Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, has announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of US$21.50 per share. All of the shares are to be sold by Immunome.
Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Raul Gonzalez-Casarrubias, Sterling Swift, and Ivana Valdez.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
